title: [Sibutramine administration in polycystic ovary syndrome treatment].
abstract: Obesity is considered important factor contributing development of PCOS. Insulin resistance, low level of serum SHBG and activation of pituitary-adrenal axis plays a major role in pathogenesis and symptoms of PCOS. The achievement of weight loss is an important factor in treatment of PCOS, but difficulties with adherences to the dietary regiment discourage physicians to use this method. In our paper we would like to show the effectiveness of such treatment and pay attention to possibilities of drug facilities in dietary approach in treatment of PCOS coexisting with obesity.
authors.affiliation: Katedra Patofizjologii Slaskiej Akademii Medycznej w Katowicach. magols@esculap.pl
authors.forename: Magdalena
authors.initials: M
authors.lastname: Olszanecka-Glinianowicz
authors.forename: Barbara
authors.initials: B
authors.lastname: Zahorska-Markiewicz
authors.forename: Urszula
authors.initials: U
authors.lastname: Jochemczyk-Banek
authors.forename: Michał
authors.initials: M
authors.lastname: Banaś
authors.forename: Aleksander
authors.initials: A
authors.lastname: Zurakowski
mesh_terms: D000293:Adolescent; D001067:Appetite Depressants / Q000627:therapeutic use*; D003503:Cyclobutanes / Q000627:therapeutic use*; D018752:Diet, Fat-Restricted; D005260:Female; D006801:Humans; D009765:Obesity / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy*; D011085:Polycystic Ovary Syndrome / Q000178:diet therapy / Q000188:drug therapy* / Q000209:etiology; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001067:Appetite Depressants; D003503:Cyclobutanes; C058254:sibutramine